Chain Drug Review - Par files latanoprost ANDA
December 10, 2001 -- Par Pharmaceutical Inc. has submitted an abbreviated new drug application to the Food and Drug Administration for latanoprost. It is the generic...
British Medical Journal - Exacerbation of angina associated with latanoprost
October 6, 2001 -- Latanoprost is a prostaglandin [F.sub.2a] analogue used to treat open angle glaucoma.[1] Ocular side effects include conjunctival hyperaemia, iris...
Market Wire - NicOx presents promising pre-clinical results on an NO-donating latanoprost derivative from its glaucoma collaboration with Pfizer
February 12, 2007 -- www.nicox.com NicOx S.A. (Eurolist: COX) today announced the presentation ofpromising preclinical results from its August 2004 collaborationagreement...
Journal of Drugs in Dermatology - Efficacy study of latanoprost and bimatoprost solutions in promoting eyelash growth in patients with alopecia areata
April 1, 2006 -- This study is currently recruiting patients. Sponsored and verified by the University of California, San Francisco. This is a single-center,...
PR Newswire - QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
October 28, 2008 -- Sustained release treatment leads to reduction in IOP of 20% from baseline at 12 weeks VANCOUVER, Oct. 28 /PRNewswire-FirstCall/ -- QLT Inc....
Market Wire - NicOx provides update on PF-03187207 and the ongoing research collaboration with Pfizer
August 25, 2008 -- August 25, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the results of adose-ranging phase 2 study...
Review of Optometry - Device squeezes more drops from latanoprost bottle; a clinical trial of the Xal-Ease delivery system.(New Science)
March 15, 2004 -- A group of researchers including myself set out to evaluate a new delivery system intended to facilitate topical instillation of latanoprost. In a...
PR Newswire - QLT reports initial proof of concept data for punctal plug delivery technology
May 12, 2008 -- Small study supports the potential for QLT's drug elution technology to reduce and sustain intraocular pressure VANCOUVER, May 12...
Market Wire - NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
May 6, 2008 -- www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S.phase 2 study, conducted by its partner Pfizer Inc, which...
